Skip to main content

Remote Job Finders (RJF)

BMO most bullish on Merck’s, bearish on BMS’ plans to contend with patent cliffs

BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for both Opdivo and Eliquis.

Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027

Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented data this week showing its clinically meaningful benefit in older patients who are able to walk.

Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen

Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cytokine release.
Scroll to top